Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. cut its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 70.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,789 shares of the biopharmaceutical company's stock after selling 25,366 shares during the period. Lecap Asset Management Ltd.'s holdings in Royalty Pharma were worth $275,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Brooklyn Investment Group boosted its holdings in Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 876 shares during the period. Blue Trust Inc. raised its position in Royalty Pharma by 362.7% in the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 943 shares during the period. Fifth Third Bancorp raised its position in Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 997 shares during the period. Spire Wealth Management raised its position in Royalty Pharma by 377.6% in the 4th quarter. Spire Wealth Management now owns 2,149 shares of the biopharmaceutical company's stock worth $55,000 after purchasing an additional 1,699 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Royalty Pharma in the 3rd quarter worth about $61,000. Institutional investors own 54.35% of the company's stock.

Analysts Set New Price Targets

RPRX has been the topic of a number of research analyst reports. StockNews.com upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Tuesday, November 5th. Citigroup dropped their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday, October 25th. Finally, TD Cowen upgraded shares of Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $41.67.

Royalty Pharma Stock Up 0.3 %

Royalty Pharma stock traded up $0.09 during mid-day trading on Wednesday, reaching $32.34. 3,662,213 shares of the company's stock were exchanged, compared to its average volume of 4,198,622. The company has a market cap of $19.05 billion, a P/E ratio of 16.76 and a beta of 0.49. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $32.72. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. The company has a fifty day moving average of $28.05 and a 200-day moving average of $27.68.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 50.53% and a return on equity of 24.65%. Sell-side analysts expect that Royalty Pharma plc will post 4.08 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a yield of 2.72%. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's payout ratio is presently 43.52%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.